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Aims Heart muscle contraction is regulated via the b-adrenergic response that leads to phosphorylation of Troponin I (TnI)
at Ser22/23, which changes the Ca2+ sensitivity of the cardiac myofilament. Mutations in thin filament proteins that
cause dilated cardiomyopathy (DCM) and some mutations that cause hypertrophic cardiomyopathy (HCM) abolish
the relationship between TnI phosphorylation and Ca2+ sensitivity (uncoupling). Small molecule Ca2+ sensitizers
and Ca2+ desensitizers that act upon troponin alter the Ca2+ sensitivity of the thin filament, but their relationship
with TnI phosphorylation has never been studied before.
Methods and
results
Quantitative in vitro motility assay showed that 30 mM EMD57033 and 100 mM Bepridil increase Ca2+ sensitivity of
phosphorylated cardiac thin filaments by 3.1- and 2.8-fold, respectively. Additionally they uncoupled Ca2+ sensitivity
from TnI phosphorylation, mimicking the effect of HCMmutations. Epigallocatechin-3-gallate (EGCG) decreased Ca2+
sensitivity of phosphorylated and unphosphorylated wild-type thin filaments equally (by 2.15+ 0.45- and 2.80+0.48-
fold, respectively), retaining the coupling. Moreover, EGCG also reduced Ca2+ sensitivity of phosphorylated but not
unphosphorylated thin filaments containing DCM and HCM-causing mutations; thus, the dependence of Ca2+ sensitiv-
ity upon TnI phosphorylation of uncoupledmutant thin filaments was restored in every case. In single mouse heart myo-
fibrils, EGCG reduced Ca2+ sensitivity of force and kACT and also preserved coupling. Myofibrils from the ACTC E361G
(DCM) mouse were uncoupled; EGCG reduced Ca2+ sensitivity more for phosphorylated than for unphosphorylated
myofibrils, thus restoring coupling.
Conclusion We conclude that it is possible to both mimic and reverse the pathological defects in troponin caused by cardiomyop-
athy mutations pharmacologically. Re-coupling by EGCG may be of potential therapeutic significance for treating
cardiomyopathies.
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1. Introduction
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy
(DCM) are common inherited diseases. HCM is detected in 1 in 500
of the adult population, and the causative mutations are overwhelming-
ly in the proteins of the cardiac muscle contractile apparatus.1,2 At least
30% of cases of idiopathic DCM are of genetic origin, and DCMwith no
additional complications such as conduction disease is usually caused
by mutations in the contractile apparatus.3,4 In many cases, the
cardiomyopathies result from missense mutations in one of the
proteins of the muscle thin filament (actin, tropomyosin, troponin I,
C, or T). Investigations of the mechanisms that cause HCM and
DCM have generally found that mutations in the muscle thin filament
cause abnormalities in the Ca2+ regulatory system of the muscle.5–7
HCM is closely associated with enhanced myofilament Ca2+ sensi-
tivity, although the process by which chronically high Ca2+ sensitivity
leads to the symptoms of HCM, hypertrophy, fibrosis, and arrhythmias,
is uncertain. In DCM, the situation is more complex. It has been
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suggested that DCM-causing mutations are associated with a reduced
Ca2+ sensitivity,8 but comprehensive surveys now show that
DCM-causing mutations in thin filament proteins can increase or de-
crease Ca2+ sensitivity.5,9 However, the DCM phenotype is always
linked to the absence of modulation of Ca2+ sensitivity by troponin I
(TnI) phosphorylation (uncoupling), and this has been proposed to
be causative of the DCM phenotype.9,10 In addition, the coupling be-
tween TnI phosphorylation and change of Ca2+ sensitivity seems to
be lost due to HCM mutations in thin filament proteins when studied
by in vitro motility assay (IVMA) techniques and by myofibrilar
assays,11 – 15 but in permeabilized muscle, this phenomenon is not
observed.16 Thus, in HCM, the relationship between TnI phosphoryl-
ation and Ca2+ sensitivity is not clear.
Uncoupling appears to be closely associated with mutations in thin
filament proteins that cause cardiomyopathies. The decrease in Ca2+
sensitivity upon phosphorylation of TnI and the corresponding increase
in the rate of Ca2+ dissociation from troponin C (TnC) is a key
component of the lusitropic response to b1-adrenergic stimulation
in the heart. The uncoupling reported in DCM and HCM is likely to
impact on cardiac reserve pathologically, and indeed, most studies of
mouse models with cardiomyopathy mutations in thin filament
proteins report a blunted response to adrenergic stimulation in vivo
(reviewed in Ref. 17).
A number of small molecules have been found that alter myofilament
Ca2+ sensitivity by binding to troponin and act as either Ca2+ sensiti-
zers or Ca2+ desensitizers. The effect of these reagents on Ca2+ sen-
sitivity is well documented, but the effect of small molecules on the
coupling between Ca2+ sensitivity and TnI phosphorylation has not
previously been considered.
EMD57033 and Bepridil are well-established Ca2+ sensitizers acting
directly upon TnC.18–20 Epigallocatechin-3-gallate (EGCG), the princi-
pal polyphenol isolated from green tea, is reported to be a Ca2+ desen-
sitizer that also acts via a binding site on TnC.21–23 Structural studies
indicate that the regulatory Ca2+ binding site (Site II in the N-terminal
lobe of TnC) is closely coupled both to the binding of the TnI switch
peptide (147–163), critical for neutralizing the inhibitory action of
TnI, and the cardiac-specific N-terminal peptide of TnI (1–30) that
contains the phosphorylatable serines 22 and 23.24–28 We have pro-
posed that DCM-causing mutations in thin filament proteins uncouple
phosphorylation from the change in Ca2+ sensitivity by disrupting this
coupled allosteric system.9,17 It is likely that Ca2+ sensitizers and desen-
sitizers binding to TnC would also have an effect on the coupling be-
tween Ca2+ sensitivity and TnI phosphorylation by modulating the
coupled system.
We have therefore investigated how EMD57033, Bepridil, and
EGCG affect the Ca2+ regulation and its modulation by phosphoryl-
ation in native human heart thin filaments and how these reagents
interact with mutations in thin filament proteins associated with
HCM or DCM. Using IVMA and single myofibril contractility, we
have confirmed the Ca2+-sensitizing effects of EMD57033 and
Bepridil and demonstrated that they also uncouple Ca2+ sensitivity
from the TnI phosphorylation level, thus mimicking the effects of
HCM-causing mutations. In contrast, EGCG decreases Ca2+ sensitiv-
ity in native thin filaments while retaining the modulation of Ca2+ sen-
sitivity by TnI phosphorylation. Moreover, EGCG has the unique
ability to restore the coupling to uncoupled HCM and DCM mutant
thin filaments and myofibrils, thus antagonizing the disease-causing
defect. This property of EGCG may be of therapeutic significance
for treating some cardiomyopathies.
2. Methods
2.1 Sources of contractile proteins
Donor heart tissue, used as control, and end-stage failing heart tissue from
explanted hearts were obtained from the Sydney Tissue Bank Sydney, Aus-
tralia.1,2 Ethical approval for collection and use of tissue samples was ob-
tained from the St Vincent’s Hospital, Sydney and Brompton, Harefield
and NHLI Research Ethics Committees.
Troponin was isolated from 100 mg of human heart muscle using an
anti-cardiac TnI mAb affinity column as described by Messer.29 Troponin
containing the TNNC1 G159D mutation was purified from explanted heart
samples as previously described.9,30,31 Recombinant TNNT2 K280N and
TNNI3 K36Qwas introduced into donor heart troponin by exchange as de-
scribed.29,32 Wild-type a-tropomyosin (Tpm1.1) and the mutants E40K,
E54K, and E180G were expressed in a baculovirus/Sf9 system with a proto-
col based on that of Akkari et al.9,33,34 Native, E361G, and E99K mutant
mouse cardiac actins were extracted from transgenic mouse hearts as
described by Song et al.35
2.2 Manipulation and measurement of TnI
phosphorylation level
Troponin isolated from human heart samples has a high level of phosphor-
ylation, which was reduced by treatment with shrimp AP (Sigma P9088).
Recombinant TnI was phosphorylated by treatment with protein kinase
A (PKA) catalytic subunit (Sigma, P2645–400) as previously described.9,32
To dephosphorylate mouse heart troponin, mice were treated with pro-
pranolol as described.10 TnI phosphorylation levels in myofibrils and iso-
lated troponin were measured by Phosphate affinity SDS–PAGE as
described;9,36 results are shown in Supplementary material online, SC.
2.3 Quantitative IVMA
Thin filaments were reconstituted with 10 nM rabbit skeletal or mouse car-
diac muscle a-actin (labelled with TRITC phalloidin), tropomyosin (40–
60 nM), and troponin (60 nM) to study Ca2+ regulation of filament motility
by the quantitative IVMA.29,37 Thin filament movement over a bed of immo-
bilized rabbit fast skeletal muscle heavy meromyosin (100 mg/mL) was
compared in paired motility chambers in which troponin varied by a single
factor (mutation, phosphorylation state, or treatment with drug). Filament
movement was recorded and analysed as previously described,38 yielding
two parameters, the fraction of filaments moving, and the speed of moving
filaments.
2.4 Contraction of isolated myofibrils
Contraction and relaxation of isolated mouse myofibrils were initiated
using a fast-solution change system and sensitive force transducer sys-
tem recently described.10 Further details are in Supplementary material
online, SA.
3. Results
3.1 Relationship between phosphorylation
and Ca21 sensitivity
We measured the Ca2+ dependence of thin filaments containing
human heart troponin by the IVMA. The assay yields two parameters,
fraction of filaments motile and sliding speed of the motile thin fila-
ments. Both parameters are Ca2+ dependent, and Ca2+ activation
curves were plotted (Figure 1). 3.9 mM Ca2+ increased the fraction of
filaments motile from 0.03 to 0.83 and the sliding speed from 1.5 to
3.0 mm/s. The EC50 and Hill co-efficient (nH) determined by fitting
the Hill equation to the data were similar for both parameters under
M. Papadaki et al.Page 2 of 12
by guest on Septem
ber 24, 2015
D
ow
nloaded from
 
all conditions; therefore, in this manuscript we have only shown the
fraction motile parameter. Full data for both parameters are shown
in Supplementary material online, SB.
Human heart troponin has a high level of TnI phosphorylation in the
1.4–1.8 mol Pi/mol range.36 This is reduced to ,0.3 mol Pi/mol by
treatment with phosphatase, see Supplementary material online, SC.
The Ca2+ sensitivity of unphosphorylated thin filaments is 1.88+
0.10 (P, 0.0001, n ¼ 16) times greater than the native phosphorylated
thin filaments as reported previously.29 nH was significantly reduced
from 2.11+ 0.18 for phosphorylated to 1.72+0.11 for unphosphory-
lated thin filaments, P ¼ 0.017, n ¼ 16. The maximum sliding speed was
not significantly affected by phosphorylation level (Table 1, Figure 1A).
We have investigated thin filaments incorporating six DCM-causing
mutations that have been shown to abolish this relationship (uncouple)
in previous studies9 and three HCM mutations that uncouple in vitro
(Figure 1B15,39).
Figure 1 Relationship between EC50 and TnI phosphorylation in native human thin filaments and thin filaments containing HCM-causing mutation
TPM1 E180G. Sliding speed and fraction of filaments motile, measured in the same experiment by IVMA, are plotted against [Ca2+] for representative
experiments. Raw data from one experiment are shown here; the mean values of EC50 from replicate experiments are shown in Table 2. Solid lines
and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated troponin (unP). Error bars represent SEM of four measure-
ments of motility in the same motility chamber. Blue, native thin filaments; purple, HCM-causing mutation TPM1 E180G present. (A) Native thin fila-
ments: phosphorylation increased EC50 (decreased Ca
2+ sensitivity) but had no effect on the maximum sliding speed or fraction of filaments motile at
saturating Ca2+. (B) Thin filaments containing TPM1 E180G HCM-causing mutation. The relationship of Ca2+ sensitivity to TnI phosphorylation is
uncoupled.
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3.2 EMD57033 and Bepridil increase Ca21
sensitivity and uncouple TnI
phosphorylation from changes in Ca21
sensitivity
EMD57033 and Bepridil substantially increased the Ca2+ sensitivity
(Figure 2A and D) and slightly increased the maximum sliding speed of
native human thin filaments as expected.
The effect of EMD57033 on EC50 for Ca
2+ activation of motility was
biphasic with a maximum at 30 mM and an EC50 in the range of 15–
20 mM (Figure 2C). Interestingly, we observed that 30 mM EMD57033
increased the Ca2+ sensitivity of thin filaments containing phosphory-
lated troponin more than unphosphorylated TnI (mean ratio EC50
P/EC50 P + EMD57033 ¼ 3.07+ 0.71, P ¼ 0.0001, n ¼ 4 in phos-
phorylated compared with a mean ratio of EC50 unP/EC50 unP +
EMD57033 ¼ 1.83+ 0.36, P ¼ 0.07, n ¼ 4 in unphosphorylated,
Table 1, Figure 2A, see Supplementary material online, SB). Consequent-
ly, in the presence of EMD57033, Ca2+ sensitivity of thin filaments was
the same, independent of the level of phosphorylation (EC50 P +
EMD57033/EC50 unP + EMD57033 ¼ 1.08+ 0.03, P ¼ 0.06, n ¼ 4).
EMD57033 increased sliding speed slightly at saturating Ca2+ concen-
tration in phosphorylated thin filaments and in unphosphorylated thin
filaments by 18.4+4.1% (P ¼ 0.02, n ¼ 4). nH was slightly decreased in
phosphorylated but not in unphosphorylated thin filaments.
EMD57033 also increased the Ca2+ sensitivity of thin filaments con-
taining the DCM-causing mutations, TPM1 E40K and E54K. In both
these cases, Ca2+ sensitivity was independent of troponin phosphoryl-
ation (uncoupled) due to the mutation (Table 1, Figure 2B).
A similar pattern of results was observed with Bepridil. The dose–re-
sponse curve was cooperative with a calculated EC50 of 52 mM
(Figure 2F). At 100 mM,which is the saturated concentration, the increase
in Ca2+ sensitivity of phosphorylated donor thin filaments (measured by
the mean ratio EC50 P/EC50 P + Bepridil) was 2.8+0.14-fold for frac-
tion motile (P, 0.0001, n ¼ 6) and 3.09+0.59-fold for sliding speed
(P ¼ 0.016, n ¼ 6), see Supplementary material online, SB.
Bepridil increased the Ca2+ sensitivity of thin filaments and also un-
coupled Ca2+ sensitivity from TnI phosphorylation, as shown by the
EC50 ratios of phosphorylated to dephosphorylated troponin (EC50
P/EC50 unP ¼ 1.73+ 0.03, P, 0.0001; EC50 P + Bepridil/EC50
unP + Bepridil ¼ 1.03+0.01, P ¼ 0.04, n ¼ 6) (Figure 2D, see Supple-
mentary material online, SB). Bepridil increased sliding speed at satur-
ating Ca2+ concentrations significantly in phosphorylated thin filaments
(14.8+3.2%, P ¼ 0.006, n ¼ 6) but did not have a significant effect in
unphosphorylated thin filaments (7.2+ 4.6%, P ¼ 0.18, n ¼ 6); it had
no significant effect on nH. Bepridil also reversibly increased the
Ca2+ sensitivity of both phosphorylated and unphosphorylated thin
filaments containing the DCM-causing TPM1 E54K mutation, and these
mutant thin filaments remained uncoupled (Table 1, Figure 2E, see
Supplementary material online, SE).
3.3 EGCG decreases Ca21 sensitivity while
retaining coupling
EGCG decreased Ca2+ sensitivity of human cardiac thin filaments mea-
sured by IVMA and at saturating concentrations (100 mM) reduced the
maximum sliding speed up to 20% but had no significant effect on nH
(Table 1, Figure 3, see Supplementary material online, SB). Titration of
EGCG at 0.074 mM Ca2+ yielded a cooperative dose–response curve
with a calculated EC50 of 70+ 7 mM for phosphorylated and 60+ 1
for unphosphorylated (Figure 3C). Unlike EMD57033 and Bepridil,
100 mM EGCG had a similar effect on the EC50 of thin filaments with
phosphorylated and unphosphorylated troponin, (mean ratio EC50 +
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Effect of EMD57033, Bepridil, and EGCG on Ca21 regulation of motility
Treatment EC50 nH DVmax EC50, TPM1 E54K DCM mutation
Native
P 0.16+0.03 (4) 2.08+0.14 (4) 1.40+0.11 (4) 0.12+0.02 (3)
unP 0.091+0.014 (4)† 1.51+0.25 (4)† 1.30+0.04 (4) 0.11+0.008 (3)
+EMD57033
P 0.057+0.010 (4)** 1.26+0.07 (4)* 1.55+0.08 (4) 0.041+0.002 (3)*
unP 0.053+0.010 (4) 1.34+0.14 (4) 1.54+0.08 (4)* 0.041+0.002 (3)*
Native
P 0.13+0.007 (8) 2.89+0.48 (8) 2.09+0.14 (8) 0.13+0.014 (3)
unP 0.072+0.002 (6)†† 1.96+0.08 (6) 2.13+0.20 (6) 0.13+0.012 (3)
+Bepridil
P 0.045+0.001 (8)** 1.94+0.08 (8) 2.40+0.15 (8)** 0.060+0.009 (3)*
unP 0.045+0.001 (6)** 2.03+0.13 (6) 2.24+0.16 (6) 0.058+0.006 (3)**
Native
P 0.14+0.03 (7) 1.61+0.19 (7) 1.91+0.18 (7) 0.11+0.01 (5)
unP 0.059+0.011 (6)†† 1.50+0.21 (6) 1.92+0.22 (6) 0.11+0.02 (5)
+EGCG
P 0.26+0.02 (7)** 1.96+0.24 (7) 1.38+0.12 (7)** 0.23+0.03 (5)*
unP 0.15+0.02 (6)**,†† 1.79+0.30 (6) 1.52+0.13 (6)* 0.071+0.005 (5)††
Paired t-test was used for EC50, nH, and DVmax (the change in velocity due to Ca
2+). EC50 values rounded to two significant figures. The number of experiments is given in brackets.
*P, 0.05, **P, 0.01, for presence and absence of reagent.
†P, 0.05, ††P, 0.01, unphosphorylated compared with phosphorylated.
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EGCG/EC50 control ¼ 2.15+ 0.45-fold for phosphorylated and
2.80+ 0.48-fold for unphosphorylated thin filaments, see Supplemen-
tary material online, SB). Therefore, the coupling of TnI phosphoryl-
ation level to changes in Ca2+ sensitivity was retained (EC50 P/EC50
unP ¼ 2.24+ 0.10, P, 0.0001, n ¼ 6; EC50 P + EGCG/EC50 unP +
EGCG ¼ 1.73+0.16, P ¼ 0.006, n ¼ 6) (Table 1, Figure 3A, see Supple-
mentary material online, SB).
3.4 EGCG restores coupling to HCM and
DCM mutant thin filaments and myofibrils
EGCG also affected Ca2+ sensitivity in thin filaments containing
mutations associated with HCM or DCM in a phosphorylation-
dependent way. This was tested with five DCM-causing mutations and
three HCM-causing mutations. EGCG decreased the Ca2+ sensitivity
of phosphorylated mutant thin filaments in a similar way to wild-type
troponin (ratio EC50 with/without EGCG was 1.36–2.85). However,
with unphosphorylated troponin, EGCG tended to have no effect or,
in the case of the three tropomyosin mutations, increased Ca2+
sensitivity (Table 2). As a result, the dependence of Ca2+ sensitivity on
TnI phosphorylation level was restored. For example, thin filaments
containing the DCM-causing TPM1 mutation E54K were uncoupled
with EC50 of 0.106+ 0.013 mM for phosphorylated and 0.114+
0.019 mM for unphosphorylated giving a ratio of 0.95+0.03 compared
with a ratio of 2.24+0.10 for wild-type thin filaments (Table 1). In the
presence of 100 mM EGCG, the EC50 was 0.23+ 0.03 mM for phos-
phorylated and 0.071+0.005 mM for unphosphorylated giving a ratio
of 3.17+0.37 (P ¼ 0.004, n ¼ 5) (Table 1, Figure 3B). A dose–response
assay for recoupling yielded an EC50 of 58.8+ 13.3 mM (Figure 3D).
Similarly, EGCG was able to reversibly restore coupling of all the thin
filamentHCMandDCM-causingmutations in this study (Table 2, Figures 4
and 5, see Supplementary material online, SF).
3.5 The effect of EGCG on contraction of
myofibrils
We studied the effect of EGCG on mouse myofibril contractility
in basally phosphorylated and dephosphorylated states, obtained
Figure 2 Effect of Ca2+ sensitizers on Ca2+ control of motility. (A, B, D and E) Fraction of filaments motile, measured by IVMA is plotted against [Ca2+]
details as in Figure 1. (A and D) Effect of Ca2+ sensitizers on Ca2+ regulation of native thin filaments. Blue, native thin filaments; orange, the presence of
30 mMEMD57033; brown, the presence of 100 mMBepridil. (B and E) Effect of Ca2+ sensitizers on Ca2+ regulation of thin filaments containing the TPM1
E54K DCM-causing mutation. Red, E54K-containing thin filaments; orange, the presence of 30 mM EMD57033; brown, the presence of 100 mM Bepridil.
(C) EMD57033 dose–response curve: EC50 was determined at a range of EMD57033 concentrations. The change in EC50 (+SEM of four measurements
of motility in the same motility chamber) is plotted for three separate experiments. (F) Bepridil dose–response curve: motility was measured at a con-
stant of 0.037 mMCa2+with increasing concentrations of Bepridil. The increase in fraction of filaments motile (+SEM of four measurements of motility
in the same motility chamber) is plotted for three separate experiments and the curve represents the fit of the pooled data to the Hill equation. Values of
parameters obtained are shown.
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by treating mice with propranolol prior to sacrifice (Table 3 ,
Figure 6).
We found that 10 mM EGCG decreased Ca2+ sensitivity of isomet-
ric force for both phosphorylated and unphosphorylated mouse myo-
fibrils equally (EC50 P/EC50 P + EGCG ¼ 0.50+ 0.06, P, 0.001,
n ¼ 9, EC50 unP/EC50 unP + EGCG ¼ 0.45+ 0.07, P, 0.00, n ¼ 5).
Consequently, the effect of phosphorylation on Ca2+ sensitivity in
wild-type myofibrils was preserved in the presence of EGCG (EC50
P + EGCG/EC50 unP + EGCG ¼ 1.64+ 0.24, P, 0.001, n ¼ 5).
As previously shown,10 in myofibrils from ACTC E361G DCM mice,
the Ca2+ sensitivity of force is uncoupled (Table 3, Figure 6). EGCG de-
creased Ca2+ sensitivity in myofibrils from ACTC E361Gmice; however,
this effect was greater in phosphorylated myofibrils than unphosphory-
lated myofibrils. Thus, EGCG restored the phosphorylation-dependent
shift in Ca2+ sensitivity for ACTC E361G myofibrils to the same level as
in wild-typemyofibrils (EC50 P + EGCG/EC50 unP + EGCG ¼ 1.62+
0.20, P, 0.01, n ¼ 5 compared with 1.82+ 0.24 for wild-type in the
absence of EGCG). nH values were similar to those found in wild-type
Figure 3 Effect of EGCG on Ca2+ control of motility. (A and B) Fraction of filaments motile, measured by IVMA, is plotted against [Ca2+], details as in
Figure 1. Raw data from one experiment are shown here; the mean values of EC50 from replicate experiments are shown in Tables 1 and 2. (A) Effect of
EGCG on Ca2+ regulation of native thin filaments. Blue, native thin filaments; green, the presence of 100 mM EGCG. (B) Effect of EGCG on Ca2+ regu-
lation of thin filaments containing TPM1 E54KDCM-causing mutation. Red, E54K-containing thin filaments; green, the presence of 100 mM EGCG. (C and
D) Dose–response curves, the fraction motile was measured at a constant [Ca2+] with increasing concentrations of EGCG for a representative experi-
ment. (C) Effect of EGCG on donor thin filaments at 0.074 mMCa2+. The inset plots the change in fraction motility with increasing EGCG concentration,
and the curve represents the fit of the pooled data to the Hill equation. Values of parameters obtained are shown. (D) Effect of EGCG on thin filaments
containing TPM1 E180G tropomyosin at 0.037 mMCa2+. Initially, motility is the same (see Figure 1); the addition of EGCG reducedmotility of phosphory-
lated and increased motility of unphosphorylated thin filaments, indicating recoupling or the restoration of the phosphorylation-dependent Ca2+ sen-
sitivity difference (see Figure 3B). Details as in Figure 2F.
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Table 2 Effect of EGCG and TnI phosphorylation on the Ca21 sensitivity of thin filaments containing HCM and DCM mutations
Mutation EC50 of thin
filaments containing
phosphorylated
troponin mM+ SEM
EC50 of thin filaments
containing
unphosphorylated
troponin mM+ SEM
Ratio EC50 P/
unP+ SEM
EC50 of thin filaments
treated with EGCG
containing
phosphorylated
troponin mM+ SEM
EC50 of thin filaments
treated with EGCG
containing
unphosphorylated
troponin mM+ SEM
Ratio EC50 P 1 EGCG/
unP 1 EGCG+ SEM
Ratio EC50
P1 EGCG/
P+ SEM
Ratio EC50
unP1 EGCG/
unP+ SEM
WT 0.14+0.03 (7) 0.059+0.011 (6)†† 2.24+0.10 (6)†† 0.26+0.02 (7)** 0.15+0.02 (6)**,†† 1.73+0.16 (6)†† 2.15+0.45(7) 2.80+0.48(6)
DCM
TPM1
E54K
0.11+0.013 (5) 0.11+0.02 (5) 0.95+0.03 (5) 0.23+0.03 (5)* 0.071+0.005 (5)†† 3.17+0.37 (5)†† 2.33+0.53(5) 0.68+0.10(5)
TPM1
E40K
0.18+0.03 (8) 0.17+0.03 (8) 1.02+0.007 (8) 0.22+0.04 (5) 0.052+0.01 (5)*,† 4.63+0.96 (5)† 1.70+0.43(3) 0.34+0.05(3)
TNNC1
G159D
0.092+0.004 (5) 0.095+0.005 (5) 0.97+0.03 (5) 0.19+0.03 (5)* 0.088+0.005 (5)*,† 2.25+0.41 (5)† 2.13+0.36(5) 0.93+0.02(5)
TNNI3
K36Q
0.18+0.03 (10) 0.18+0.04 (10) 1.02+0.05 (10) 0.19+0.02 (5) 0.10+0.009 (5)*,† 1.97+0.12 (5)† 2.32+0.29(3) 1.28+0.04(3)
ACTC
E361G
0.087+0.002 (5) 0.080+0.002 (5) 1.08+0.02 (5) 0.20+0.02 (5)** 0.081+0.002 (5)†† 2.41+0.28 (5)†† 2.27+0.28(5) 1.01+0.02(5)
HCM
TPM1
E180G
0.086+0.013 (3) 0.087+0.011 (3) 0.98+0.02 (3) 0.11+0.01 (5)* 0.048+0.003 (5)*,† 2.41+0.32 (5)† 1.36+0.10(3) 0.51+0.06(3)
TNNT2
K280N
0.11+0.007 (5) 0.10+0.004 (5) 1.08+0.04 (5) 0.20+0.03 (5)* 0.10+0.004 (5)† 1.96+0.24 (5)† 2.15+0.18(3) 1.09+0.006(3)
ACTC
E99K
0.074+0.005 (5) 0.074+0.005 (5) 0.99+0.02 (5) 0.21+0.03 (5)** 0.10+0.007 (5)*,†† 2.03+0.21 (5)†† 2.85+0.28(5) 1.43+0.13(5)
Ratios: single value t-test compared with 1. ANOVA analysis of this data set is shown in Supplementary material online, SE. EC50 values rounded to two significant figures. The number of experiments is given in brackets.
*P, 0.05, **P, 0.01, for the presence and absence of EGCG using paired t-test.
†P, 0.05, ††P, 0.01, unphosphorylated compared with phosphorylated using paired t-test.
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myofibrils (Table 3). The duration of the initial, nearly isotonic, phase of
relaxation, tLIN, in phosphorylated and unphosphorylated ACTC E361G
myofibrils was restored to wild-type values (Table 3). EGCG decreased
the rate of force development (kACT) but did not affect maximum force.
kACT was decreased by EGCG in unphosphorylated wild-type myofi-
brils (decreased by 22.8%, P ¼ 0.059, n ¼ 15) as well as in phosphory-
lated and unphosphorylated ACTC E361G (decreased by 23%, P, 0.05,
n ¼ 10 and by 21%, P, 0.001, respectively, n ¼ 11).
4. Discussion
In previous studies, it was found that mutations in proteins of the car-
diac muscle thin filament that are associated with inherited cardiomy-
opathies (HCM and DCM) alter myofibrillar Ca2+ sensitivity. They also
cause the modulation of myofilament Ca2+ sensitivity to become inde-
pendent of the PKA-dependent phosphorylation of TnI. We have
named this phenomenon uncoupling. Moreover, this uncoupling effect
may be sufficient to generate the disease phenotype of familial
DCM.9,17 We have investigated whether small molecules might be
able to mimic or reverse the molecular effects of mutations.
The Ca2+ sensitizers EMD57033 and Bepridil, known to bind to
TnC, induce uncoupling in wild-type thin filaments, thus mimicking
the effects of HCMmutations. The Ca2+ desensitizer EGCG has an op-
posite effect. It preserves coupling in wild-type troponin and restores
coupling to thin filaments with HCM- and DCM-causing mutations in
TnI, TnC, TnT, tropomyosin, and actin, thus antagonizing the effect
of the HCM or DCM mutation. These findings suggest the potential
of EGCG for treating the symptoms of inherited cardiomyopathies.
4.1 Ca21 sensitizers mimic the effects of
HCM-causing mutations in thin filaments
Both EMD57033 and Bepridil increase Ca2+ sensitivity of phosphory-
lated thin filaments by 2.8- and 2.9-fold, measured by quantitative
Figure 4 Coupling is restored to HCM and DCM mutations by EGCG. Fraction of filaments motile, measured by IVMA in the presence of 100 mM
EGCG, is plotted against [Ca2+] for representative single experiments. Details as in Figure 1. Red lines, thin filaments containing DCM-causing mutations;
Purple lines, thin filaments containing HCM-causing mutations. The mean values of EC50 from replicate experiments are plotted in Figure 5 and summar-
ized in Table 2.
Figure 5 The re-coupling effect of EGCG. The ratio of EC50 phos-
phorylated/EC50 unphosphorylated (coupling constant) is plotted in
the absence (blue) and presence (green, red, and purple) of
100 mM EGCG. Green, control troponin; red, DCM-causing mutants;
purple, HCM-causing mutants, error bars are +SEM. All the mutant
samples are uncoupled, but the coupling constant is restored to con-
trol levels by EGCG. Data from Table 2.
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IVMA, in common with previous measurements.40,41 However, it has
not been shown before that they increase Ca2+ sensitivity of unpho-
sphorylated thin filaments considerably less than phosphorylated thin
filaments. As a consequence, Ca2+ sensitivity becomes independent
of the TnI phosphorylation level (uncoupled).
The effect of Ca2+ sensitizers is analogous to the effect of
HCM-causing mutations in vitro (Table 2) where both an increase in
the Ca2+ sensitivity and uncoupling of the Ca2+ sensitivity from the
TnI phosphorylation are observed. Uncoupling due to HCM mutations
was first reported in 200113 and several more thin filament mutations
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Effect of phosphorylation, ACTC E361G mutation, and EGCG on Ca21 regulation of myofibril contraction
Fmax (kN/m
2) EC50 (mM) nH kACT (s
21) tLIN (ms) kREL (s
21)
WTa
P 100.9+6.3 (14) 0.93+0.06 (11) 10.43+1.84 (10) 4.16+0.43 (11) 50.8+3.5 (12) 35.0+4.0 (10)
unP 87.1+6.0 (16) 0.51+0.06 (14)††† 4.74+0.66 (13)†† 4.50+0.24 (15) 67.0+4.2 (16)† 23.2+2.8 (11)†††
WT + EGCG
P 92.5+5.0 (15) 1.85+0.17 (9)*** 4.30+0.85 (8)** 4.44+0.24 (15) 46.7+3.9 (12) 41.0+4.0 (12)
unP 92.6+8.9 (8) 1.13+0.13 (5)††,*** 5.08+1.24 (5) 3.47+0.55 (6) 88.9+9.9 (7)†††,* 22.3+1.2 (7)††
E361Ga
P 93.5+8.9 (11) 0.38+0.05 (12)§§§ 5.39+1.26 (9)§ 4.51+0.32 (13) 75.4+6.5 (10)§§ 21.6+2.8 (10)§§§
unP 89.3+8.6 (10) 0.43+0.06 (10) 4.48+0.70 (8) 4.12+0.32 (11) 70.8+9.7 (11) 21.6+2.1 (10)
E361G + EGCG
P 89.1+4.5 (12) 2.07+0.20 (5)***,‡‡‡ 7.18+1.54 (5) 3.43+0.20 (13)*,§,‡‡ 49.7+3.3 (12)** 31.0+2.6 (12)*,§
unP 96.3+11.1 (11) 1.28+0.10 (8)††,***,‡‡‡ 4.14+0.42 (7)† 3.25+0.26 (11)***,‡‡ 63.0+4.7 (12)†,§ 31.0+2.0 (12)**,§§,‡‡
The number of experiments is given in brackets. Statistical analysis carried out by un-paired t-test (equal variance).
aVikhorev et al.11
*P, 0.05, **P, 0.01, ***P, 0.001, EGCG treated compared with no EGCG.
†P, 0.05, ††P, 0.01, †††P, 0.001, unphosphorylated compared with phosphorylated.
§P, 0.05, §§P, 0.01, §§§P, 0.001, ACTC E361G compared with wild type.
‡P, 0.05, ‡‡P, 0.01, ‡‡‡P, 0.001, ACTC E361G EGCG treated compared with no EGCG wild-type.
Figure 6 EGCG restores the relationship between Ca2+ sensitivity of force production and TnI phosphorylation in wild-type and ACTC E361Gmouse
myofibrils. Phosphorylation level was reduced by propranolol treatment and measured by phosphate affinity SDS–PAGE. Basally phosphorylated wild-
type was 1.02+0.03 and ACTC E361G was 1.08+0.01 mol Pi/mol TnI. For propranolol-treated (dephosphorylated) muscle, the phosphorylation level
was 0.30+0.04 in wild type and 0.34+0.07 mol Pi/mol TnI for ACTC E361G. (A) Ca2+ activation curves for ACTC E361G myofibrils in the presence
(green) and absence (red) of 10 mM EGCG. Solid lines and points, phosphorylated troponin (P); dotted lines and open points, unphosphorylated tropo-
nin (unP). The plot shows averaged isometric tension+ SEM from 11 to 14 myofibrils for experiments performed at SL ¼ 2.17 mm. EGCG shifts the
activation curve to the right and restores the difference between phosphorylated and unphosphorylated myofibrils. (B) Effects of the ACTC E361G mu-
tation, phosphorylation, and EGCG on the mean EC50 (+SEM) for myofibril isometric contraction. Significant differences, calculated by t-test, between
phosphorylated and unphosphorylated myofibrils are indicated: **P, 0.01; ***P, 0.001. Data from Table 3.
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have subsequently been demonstrated by in vitro assays,5,17 as the TPM1
E180G mutation, shown in Figure 1B, demonstrates.
4.2 Mechanistic considerations of Ca21
sensitizers
Since both EMD57033 and Bepridil appear to modulate Ca2+ sensitiv-
ity with a minimal effect on the sliding speed in IVMA or maximum iso-
metric force in muscle fibres,10,42 it is likely that they are acting on
troponin rather than the cross-bridge cycling mechanism in our
systems.
The Ca2+ sensitivity of cardiac troponin is modulated by the unique
N-terminal peptide of TnI (1–30) that contains the PKA phosphoryl-
ation sites, Ser22 and 23. When unphosphorylated, the peptide inter-
acts with the N-terminal domain of TnC, close to the regulatory
Ca2+-binding site and this interaction is lost or reduced when the
two serines are phosphorylated.43,44 The change in Ca2+ sensitivity
with TnI phosphorylation is a two- to three-fold reduction.
Bepridil is suggested to displace TnI 1–30 and/or the linker helix TnI
31–70.20,45 EMD57033 is believed to bind to the C-terminal domain of
TnC and also displaces the TnI 31–70 peptide.18,19,46 Thus, both these
compounds could act allosterically by interfering with the modulation
of Ca2+ sensitivity due to Ser22/23 phosphorylation, resulting in
uncoupling.
Interestingly, in experiments measuring isometric force in cardiac
muscle myofibrils, EMD57033 increased Ca2+ sensitivity but only
caused uncoupling at short sarcomere lengths. Thus, the uncoupling
phenomenon may be graded rather than all-or-none. One possibility
is that uncoupling may be related to Ca2+ sensitivity if the Ca2+ sensi-
tizer shifts the conformational equilibrium so far towards the
N-terminal bound conformation that it cannot be significantly influ-
enced by phosphorylation of the N-terminal peptide of TnI (see Sup-
plementary material online, SD). However, the Ca2+-sensitizing
property of these compounds does not necessarily involve the same
molecular mechanism as uncoupling.
The actions of small molecules that uncouple highlight the crucial
role of the allosteric coupling between the TnI 1–30 peptide and
ligand-binding sites that could be remotely located. Likewise, it is not-
able that DCM-causing mutations that uncouple are distributed in all
the proteins of the thin filament, also demonstrating long-range allo-
steric interactions.9,47 We have proposed that these mutations desta-
bilize the unphosphorylated state of the 1–30 peptide.9
4.3 The Ca21 desensitizer EGCG restores
coupling to thin filaments with HCM and
DCM mutations
Our observation that EGCG reduces Ca2+ sensitivity two- to three-
fold both in human thin filaments and in mouse myofibrils with only
small effects on maximum sliding speed, isometric force or Hill
coefficient, is in accord with previous measurements in skinned cardiac
muscle fibres.21,23 Moreover, we have demonstrated that the
phosphorylation-dependent shift in myofilament Ca2+ sensitivity is
unaffected by EGCG in both isolated filaments and intact myofibrils,
in contrast to the Ca2+ sensitizers (Figures 2, 3, and 6).
EGCG was also able to decrease the Ca2+ sensitivity of phosphory-
lated thin filaments containing HCM- and DCM-causing mutations;
however, it had different effects on phosphorylated and unphosphory-
lated thin filaments. With phosphorylated troponin, EGCG decreased
Ca2+ sensitivity similarly to wild-type troponin, but EGCG either had
no effect or increased Ca2+sensitivity with unphosphorylated troponin
(Table 2). This resulted in the restoration of the coupling of Ca2+ sen-
sitivity change to TnI phosphorylation (Figures 3, 4, and 5).
Several studies have located EGCG binding in the C-terminal domain
of TnC in the region of the hydrophobic cleft.21,22,46 Molecular dynam-
ics (MD) simulation suggests that it can bind in several interchangeable
orientations,46 and unlike EMD57033, EGCG can bind to the
C-terminal domain of cTnC even in the presence of TnI 34–71 helix.46
We suggest that it is possible that EGCG can re-stabilize the TnI–TnC
interaction, restoring the Ca2+ response to phosphorylation found in
DCM and HCM. MD calculations indicate that the uncoupling mutation
cTnC G159D strengthens TnI 34–71 helix binding to the hydrophobic
cleft while EGCGweakens this interaction,46 compatible with their op-
posite effects on coupling.
4.4 Effects of EGCG on myofibrillar
contractility
EGCG decreased Ca2+ sensitivity in phosphorylated and unpho-
sphorylated wild-type myofibrils by approximately two-fold but did
not change the relaxation parameters tLIN and kREL in phosphorylated
myofibrils (Table 3). The rate of force development (kACT), measured at
high Ca2+, was unchanged in myofibrils with phosphorylated TnI and
slightly decreased (P ¼ 0.059) in unphosphorylated myofibrils. As
kACT depends strongly on the Ca
2+ concentration,10 we conclude
that EGCG shifts the [Ca2+]–kACT relationship towards higher Ca
2+
concentration in agreement with IVMA data (Table 1). Thus, unlike
EMD57033, EGCG decreases cross-bridge activation kinetics.10
EGCG reduced Ca2+ sensitivity and kACT in both phosphorylated
and unphosphorylated ACTC E361G myofibrils. In addition, it restored
the lost difference in Ca2+ sensitivity between phosphorylated and un-
phosphorylated myofibrils and also the difference in the relaxation par-
ameter tLIN (Table 3). The observation that EGCG does not affect the
EC50 P/EC50 unP or tLIN in wild-type myofibrils but changes them in
ACTC E361G suggests that EGCG can restore coupling in ACTC
E361G myofibrils independently of its Ca2+-desensitizing function.
Although uncoupling can be clearly demonstrated at the level of
skinned muscle fibres or myocytes with thin filament mutations causing
DCM,35,48,49 this does not appear to be true for HCM-causing muta-
tions, despite being indistinguishable at the single filament level. A near-
normal response of Ca2+ sensitivity to TnI phosphorylation has been
reported for TNNC1 L29Q and TPM1 E180G in transgenic mice50,51
and TNNI3 R145W and TNNT2 K280N in human heart myectomy
samples.16 Despite this, both DCM- and HCM-linked mutations in
transgenic mice models are associated with an impaired response to
b1-adrenergic stimulation and reduced cardiac reserve as would be
expected if uncoupled15,35 (reviewed by Messer17). The physiological
manifestations of the uncoupling seen in unloaded filaments require
further investigation.
4.5 Clinical relevance of re-coupling
by EGCG
Ca2+ antagonists have been suggested as being potentially useful for
treatment of HCM.52 EGCG represents a new class of Ca2+ antago-
nists with a very favourable functional profile. EGCG acts directly on
the Ca2+ regulatory system of the thin filament that is also the main tar-
get of HCM-causing mutations in sarcomeric proteins.5 By binding to
troponin, it decreases the enhanced Ca2+ sensitivity characteristic of
HCM while also reversing the uncoupling effect we observed in
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HCM mutations. The ability to restore coupling to DCM mutant myo-
fibrils could be beneficial, since this was proposed to be the primary
cause of DCM, but the reduction in Ca2+ sensitivity in cases where
the mutation also reduces Ca2+ sensitivity may be deleterious.
EGCG has a wide range of pharmacological properties; indeed, it has
been cited as an example of a promiscuous molecule.53 Moreover, low
doses of EGCG have a positive inotropic effect in intact heart muscle,
due to effects on the ryanodine receptor type 2, Na+-K+ ATPase and
Na+-Ca2+ exchanger, that may override the Ca2+-desensitizing effect
in the contractile apparatus.54,55
Although EGCG is too non-specific to be a viable drug for treating
HCM, this study has demonstrated a significant proof of principle: it is
possible to directly reverse the molecular mechanism of HCM-causing
mutations pharmacologically. The coupling of Ca2+ sensitivity to cTnI
phosphorylation has been demonstrated to be a labile property of
troponin. HCM or DCMmutations and Ca2+ sensitizers can induce un-
coupling, indicating that small perturbations can destabilize tropo-
nin.9,17,32 It is very unusual to find a reagent that will give a gain of
function by apparently restoring the native conformational state in
the presence of mutations that destabilized this state.
Our findings provide a starting point for investigating molecules
related to EGCG that may be more efficacious and act specifically
on troponin.56
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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